The lead of preclinical research at Amylyx Pharmaceuticals discussed the literature supporting AMX0114’s target and its upcoming trial design.
Evan Mizerak
Advertisement
Articles by Evan Mizerak
Advertisement
Latest Updated Articles
Evan Mizerak, on Developing an ASO Targeting CAPN2 for ALSPublished: March 7th 2024 | Updated:
Advertisement
Advertisement
